



ENTERED

1636

MAR 22 2002

RECEIVED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/369,883A

DATE: 03/13/2002

TIME: 09:26:31

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF3\03132002\I369883A.raw

#13

3 <110> APPLICANT: Crouzet, Joel
 4 Pitard, Bruno
 6 <120> TITLE OF INVENTION: Formulation of Stabilised Cationic Transfection Agent
 (s)/Nucleic Acid
 7 Particles
 9 <130> FILE REFERENCE: 3806.0448
 11 <140> CURRENT APPLICATION NUMBER: 09/369,883A
 12 <141> CURRENT FILING DATE: 1999-08-09
 14 <150> PRIOR APPLICATION NUMBER: PCT/FR98/00222
 15 <151> PRIOR FILING DATE: 1998-02-06
 17 <150> PRIOR APPLICATION NUMBER: FR97/01,467
 18 <151> PRIOR FILING DATE: 1997-02-10
 20 <160> NUMBER OF SEQ ID NOS: 2
 22 <170> SOFTWARE: PatentIn version 3.0
 24 <210> SEQ ID NO: 1
 25 <211> LENGTH: 9
 26 <212> TYPE: PRT
 C--> 27 <213> ORGANISM: Artificial
 29 <220> FEATURE:
 30 <223> OTHER INFORMATION: adjuvant compound, comprising a peptide unit having Seq ID 1,
 for
 31 use in transfection compositions; such adjuvant compound can be
 32 artificially sequenced and/or derived, for example, from a portio
 33 n of a histone, a nucleolin, or a protamine
 35 <400> SEQUENCE: 1
 37 Lys Thr Pro Lys Lys Ala Lys Lys Pro
 38 1 5
 40 <210> SEQ ID NO: 2
 41 <211> LENGTH: 8
 42 <212> TYPE: PRT
 C--> 43 <213> ORGANISM: Artificial
 45 <220> FEATURE:
 46 <223> OTHER INFORMATION: adjuvant compound, comprising a peptide unit having Seq ID 2,
 for
 47 use in transfection compositions; such adjuvant compound can be
 48 artificially sequenced and/or derived, for example, from a portio
 49 n of a histone, a nucleolin, or a protamine
 51 <400> SEQUENCE: 2
 53 Ala Thr Pro Ala Lys Lys Ala Ala
 54 1 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/369,883A

DATE: 03/13/2002

TIME: 09:26:32

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF3\03132002\I369883A.raw

L:27 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:1
L:43 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:2